Toxicology study delays QLT's phase 2a Atrigel/octreotide program in acromegaly

By Lisa Kerner

Erie, Pa., May 18 - QLT Inc. is delaying the start of its phase 2a Atrigel/octreotide program in acromegaly patients following adverse findings in an ongoing primate toxicology study.

This decision to delay the trial was made in cooperation with the Food and Drug Administration, according to a company news release.

The phase 2a 16-patient study was expected to start in the third quarter of 2006, with preliminary data expected in March 2007.

QLT said it plans to submit final data from the ongoing toxicology study to the FDA by the end of the year.

The delay will save the company about $1 million in research and development costs for 2006.

QLT is a Vancouver, B.C.-based biopharmaceutical company developing treatments for eye diseases and dermatological and urological conditions.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.